X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The proceedings will be used to advance EM-113, a novel uncompetitive fast-off NMDAR agonist, into a Phase 2 clinical trial in a subset of ASD patients with elevated glutamate levels in the brain, and accelerate the development of NMDAR antagonist product candidates.
Lead Product(s): EM-113
Therapeutic Area: Neurology Product Name: EM-113
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $40.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing February 15, 2023
Details:
Under the DoD award, EuMentis will conduct preclinical TBI studies in validated large animal model in collaboration with Dr. Todd Killbaugh at the Children’s Hospital of Philadelphia and plans to advance its lead NMDA receptor antagonist candidate for TBI to clinic in 2024.
Lead Product(s): Undisclosed
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: DOD
Deal Size: $3.0 million Upfront Cash: Undisclosed
Deal Type: Funding February 08, 2023
Details:
EM-036 has demonstrated superior efficacy in preclinical Alzheimer's disease and autism spectrum disorders models compared to current standard of care.
Lead Product(s): EM-036
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 13, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
